These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27769558)

  • 1. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
    Bilotti E; Vesole DH; McBride L; Schmidt L; Gao Z; Gilani M; McNeill A; Bednarz U; Richter J; Mato A; Graef T; Siegel DS
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):558-562. PubMed ID: 27769558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
    Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
    Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
    Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
    Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
    Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
    Jung SH; Lee SE; Lee M; Kim SH; Yim SH; Kim TW; Min CK; Chung YJ
    Haematologica; 2017 Nov; 102(11):e456-e459. PubMed ID: 28775122
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
    Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
    Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
    Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC; Mazumder A; Vesole DH; Kaufman JL; Colson K; McKenney M; Lunde LE; Feather J; Maglio ME; Warren D; Francis D; Hideshima T; Knight R; Esseltine DL; Mitsiades CS; Weller E; Anderson KC
    Blood; 2014 Mar; 123(10):1461-9. PubMed ID: 24429336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
    Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
    Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
    Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
    Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
    Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
    Cohen A; Spektor TM; Stampleman L; Bessudo A; Rosen PJ; Klein LM; Woliver T; Flam M; Eshaghian S; Nassir Y; Maluso T; Swift RA; Vescio R; Berenson JR
    Br J Haematol; 2018 Jan; 180(1):60-70. PubMed ID: 29164606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.